ALK4290

ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3].

Product Specifications

CAS Number

[1251528-23-0]

Product Name Alternative

AKST4290

UNSPSC

12352005

Target

CCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/alk4290.html

Purity

99.79

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC(NC([C@@H](CC2)N(C3CCN(CC4=CC=C(Cl)C(C)=C4)CC3)C2=O)=O)=NC(C)=C1)N(C)C

Molecular Formula

C27H34ClN5O3

Molecular Weight

512.04

References & Citations

[1]NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1.|[2]Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila) . May-Jun 2020; 9 (3) :250-259.|[3]Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic